Loading...
Loading...
Sucampo Pharmaceuticals.
SCMP today announced that
its subsidiary, Sucampo AG, has received a $15 million milestone payment
from Abbott's
ABT subsidiary, Abbott Japan Co., Ltd. (Abbott),
pursuant to the existing license, commercialization, and supply
agreement between Sucampo Pharma Ltd. (SPL), SPI's subsidiary, and
Abbott. The milestone payment was triggered by the first sale of AMITIZA®
(lubiprostone) capsule 24 μg in Japan. AMITIZA is available through
Abbott in Japan as a prescription medication for chronic constipation
not caused by organic diseases, and was launched to primary care and
specialist physicians on November 21, 2012.
“For years, millions of patients in Japan have been suffering from
chronic constipation,” said Sucampo's Chairman,
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in